Regulatory Counsel

0910-AI65 202110 The Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions 0910 Food and Drug Administration FDA 0900 Department of Health and Human Services HHS Revocation of Methods of Analysis Regulation

The proposed rule revokes 2.19 (21 CFR 2.19), which states that it is FDA policy to use the methods of analysis of the AOAC International as published in the 1980 edition of Official Methods of Analysis of the Association of Analytical Chemists for FDA enforcement programs when the method of analysis is not prescribed in a regulation. Repeal of this regulation would eliminate an unnecessary policy.

]]> Info./Admin./Other First Time Published in The Unified Agenda Proposed Rule Stage No No 21 CFR 2.19 FD&C Act 15 U.S.C. 402 15 U.S.C. 409 21 U.S.C. 321 21 U.S.C. 331 21 U.S.C. 335 21 U.S.C. 342 and 343 21 U.S.C. 3346a 21 U.S.C. 348 21 U.S.C. 351 and 352 21 U.S.C. 355 21 U.S.C. 360b 21 U.S.C. 361 and 362 21 U.S.C. 371 and 372 21 U.S.C. 374 42 U.S.C. 7671 et seq. No NPRM 03/00/2022 No No None No No No No Nadine Dominique Regulatory Counsel 0910 Food and Drug Administration FDA 301 348-1868 nadine.dominique@fda.hhs.gov 10903 New Hampshire Ave, Building 32, Room 4343, Silver Spring MD 20993